Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma

Bone Marrow Transplantation

Volumn 40, Issue 8, 2007, Pages 759-764

  Przepiorka, D ^a   Buadi, F ^a   McClune, B ^a   Franz, G ^a   Walsh, W ^a   White, F ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; INTERFERON; MELPHALAN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THALIDOMIDE; THIOTEPA; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG MEGADOSE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK FACTOR; STEM CELL MOBILIZATION; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 34948862162     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705814     Document Type: Article

References (24)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
2. Barlogie B, Jagannath -S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
3. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253.
4. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
5. Levy V, Katsahian S, Fermand JP, Mary JY, Chevret S. A meta-analysis on data from 575 patients with multiple myelopla randomly assigned to either high-dose therapy or conventional therapy. Medicine 2005; 84: 250-260.
6. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
7. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-3294.
8. Jantunen E, Itala M, Siitonen T, Koivunen E, Leppa S, Juvonen E et al. Late non-relapse mortality among adult autologous stem cell transplant recipients: A nation-wide analysis of 1482 patients transplanted in 1990-2003. Eur J Haematol 2006; 77: 114-119.
9. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95: 3273-3279.
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
11. Qumsiyeh MB, Tharapel SA. Interphase detection of trisomy 12 in B-cell chronic lymphocytic leukemia by fluorescence hybridization in situ. Leukemia 1992; 6: 602-605.
12. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J 2004; 4: 103-112.
13. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95 349-353.
14. Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1161-1165.
15. Del Canizo M, Amigo M, Hernandez JM, Sanz G, Nunez R, Carreras E et al. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation. Haematologica 2000; 85: 403-409.
16. Sevilla J, Rodriguez A, Hernandez-Maraver D, de Bustos G, Aguado J, Ojeda E et al. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Ann Hematol 2002; 81: 11-15.
17. Laurenti L, Chiusolo P, Garzia MG, Zini G, Sora F, Piccirillo N et al. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. Haematologica 2002; 87 59-66.
18. Amigo ML, Del Canizo MC, Hernandez JM, Gonzalez MB, Gutiérrez N, Mateos MV et al. Clonal myelodysplastic cells present in apheresis product before transplantation. Leukemia 1998; 12: 1497-1499.
19. Abruzzese E, Radford JE, Miller JS, Vredenburgh JJ, Rao PN, Pettenati MJ et al. Detection of abnormal clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 1999; 94: 1814-1819.
20. Kroger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006; 37: 183-189.
21. Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA et al. Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578-2585.
22. Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 1997; 20: 737-743.
23. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128-3135.
24. Yakoub-Agha I, De La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients - report of the Frenck Society of Bone Marrow Transplantation. J Clin Oncol 2000; 18: 963-971.